Aurobindo Pharma-MSD Pact Lifts Shares 4% on NSE 2024

Stock jumps after biologics contract announcement

Aurobindo Pharma shares rose over 4% on June 3 after the company said its wholly-owned subsidiary, TheraNym Biologics, signed a Master Service Agreement (MSA) with Merck Sharpe & Dohme Singapore Trading (MSD). The agreement is for contract manufacturing of biological products for both domestic and international markets. The announcement put the spotlight on Aurobindo’s plans to build a scaled biologics manufacturing platform, with a new facility planned in Telangana. The stock move reflected investor focus on the contract manufacturing opportunity in biologics, where large pharma relationships can anchor long-term capacity creation.

What the agreement covers

Under the MSA, TheraNym will manufacture biologics on behalf of MSD. The arrangement includes building manufacturing infrastructure, producing products, and supplying them to MSD. Aurobindo said the arrangement is expected to kick off by FY27. The agreement was described as effective May 31, 2024.

Telangana facility: capex, location, and scale

Aurobindo Pharma said it will spend ₹1,000 crore to set up a biologics manufacturing facility at Borapatla in Telangana. The location was also specified as Borapatla (V), Hathnoora Mandal, Medak District, Telangana. The facility will feature large-scale bioreactors for mammalian cell culture products. It will also include a vial filling isolator line designed to manufacture commercial drug products.

Capacity details: 25-30 million vials a year

The vial filling isolator line is expected to support production at a rate of 25-30 million vials annually. Aurobindo said TheraNym will build the manufacturing facility, manufacture the products, and supply them to MSD as per the arrangement. The company has positioned the planned capacity as commercial-scale, with the contract expected to begin from FY27.

How the stock traded on June 3

The announcement drove higher trading in Aurobindo Pharma shares on the NSE. Around 1 pm, the stock was at ₹1,218.90 after touching an intraday high of ₹1,230. In another update from later in the session, at around 3.14 pm, the shares were trading 3.55% higher at ₹1,227.80 compared with the previous close of ₹1,185.70. The stock’s intraday high and low were reported at ₹1,230 and ₹1,205.55, respectively.

Broker view: Macquarie raises target to ₹1,385

After the development, brokerage Macquarie raised its price target on Aurobindo Pharma to ₹1,385 and maintained an ‘outperform’ rating. The brokerage described the biologics contract manufacturing (CMO) contract as a first of its kind from a large pharma player for Aurobindo. It also highlighted a potential upside of around ₹170 per share linked to the pact.

Background: LOI in October, deadline extended to May 31

The MSA follows earlier steps taken by Aurobindo’s biologics arm. Last year in October, CuraTeQ Biologics and Merck Sharp & Dohme Singapore Trading Pte Ltd and its affiliates (MSD) had signed a letter of intent for contract manufacturing operations for biologics. The parties had intended to conclude negotiations by March 31, 2024, and later extended the deadline to May 31. The new MSA formalises the next phase, including facility creation and supply commitments.

Management commentary and pipeline discussions

Satakarni Makkapati, Chief Executive Officer of Biologics, Vaccines and Peptides at Aurobindo Pharma, said the company will also be in talks with a few multi-national companies to explore contract development through its arm CuraTeq. The comments were shared in an interaction with CNBC-TV18. The stated objective of these efforts is to pursue biologics contract manufacturing deals aimed at tapping the originator biologics market.

Market context: originator biologics at $100-350 billion

Aurobindo’s push into biologics manufacturing is aimed at capturing a share of the originator biologics market, which was cited at around $100-350 billion. The size of the market underlines why large-scale mammalian cell culture capacity and fill-finish capabilities are closely watched by investors and industry participants. For Aurobindo, the MSD agreement is tied to creating dedicated infrastructure and building credentials in biologics manufacturing for global clients.

Key facts at a glance

Conclusion

Aurobindo Pharma’s MSA with MSD puts a clear timeline and infrastructure plan behind its entry into biologics contract manufacturing, with a ₹1,000 crore facility planned in Telangana and a stated FY27 kickoff. The market responded with a more than 4% rise in the stock during June 3 trade, while Macquarie raised its price target to ₹1,385. The next key marker for investors will be execution progress on the Borapatla facility and the transition from build-out to commercial supply under the MSD arrangement.